These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26975633)

  • 41. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
    Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
    Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
    Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
    Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
    Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
    Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
    McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
    Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy.
    Chow JP; Man WY; Mao M; Chen H; Cheung F; Nicholls J; Tsao SW; Li Lung M; Poon RY
    Mol Cancer Ther; 2013 Nov; 12(11):2517-28. PubMed ID: 23979918
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
    Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
    Min A; Im SA; Yoon YK; Song SH; Nam HJ; Hur HS; Kim HP; Lee KH; Han SW; Oh DY; Kim TY; O'Connor MJ; Kim WH; Bang YJ
    Mol Cancer Ther; 2013 Jun; 12(6):865-77. PubMed ID: 23512992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
    Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
    Samol J; Ranson M; Scott E; Macpherson E; Carmichael J; Thomas A; Cassidy J
    Invest New Drugs; 2012 Aug; 30(4):1493-500. PubMed ID: 21590367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
    van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro analysis of PARP inhibitor nanoformulations.
    Baldwin P; Tangutoori S; Sridhar S
    Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):59-61. PubMed ID: 29593397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
    Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
    Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
    Lai FF; Li J; Ji M; Zhou Q; Wang LY; Chen XG
    Yao Xue Xue Bao; 2016 Jun; 51(6):907-12. PubMed ID: 29879343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.
    Jelinic P; Levine DA
    Mol Cancer Ther; 2014 Jun; 13(6):1645-54. PubMed ID: 24694947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.